Alteogen disclosed for the first time that the first global license partner for its subcutaneous injection (SC) formulation-switch platform technology, ALT-B4, was the French drugmaker Sanofi.
Alteogen said on the 18th that Sanofi was the counterparty to the ALT-B4 technology out-licensing deal signed in 2019. The deal was disclosed at the time as a nonexclusive license agreement worth a total of $1.373 billion (about 1.9 trillion won), but the partner was not disclosed under the contract terms.
ALT-B4 is a technology based on Alteogen's Hybrozyme platform that converts intravenous (IV) formulation medicines into subcutaneous (SC) formulations. It can shorten administration time and improve patient convenience, drawing interest from global pharmaceutical companies.
Starting with the agreement with Sanofi, Alteogen has signed ALT-B4 license deals to date with eight global pharmaceutical companies, including MSD, AstraZeneca, GSK, Daiichi Sankyo, Biogen, Sandoz and Intas.
Chief Executive Jeon Tae-yeon of Alteogen said, "By disclosing to the market the partner that had remained undisclosed, this will serve as an opportunity to once again confirm the competitiveness of the ALT-B4 platform technology," and added, "We expect that interest in ALT-B4 will further rise with the partner disclosure and news of clinical development progress."
Jeon added, "ALT-B4 is being applied across various modalities, including monoclonal antibodies, bispecific antibodies and antibody-drug conjugates (ADC)," and said, "Its scope of use is expanding because it can offer patients faster and more convenient administration options across multiple therapeutic areas, including oncology and autoimmune diseases."